ASND Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -880.05% beat DBV Technologies SA's return on equity of --.

Ascendis Pharma AS has a consensus price target of $211.35, signalling upside risk potential of 48.14%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 246.92%. Given that DBV Technologies SA has higher upside potential than Ascendis Pharma AS, analysts believe DBV Technologies SA is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.540, which suggesting that the stock is 45.961% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than DBV Technologies SA quarterly revenues of --. Ascendis Pharma AS's net income of -$41M is lower than DBV Technologies SA's net income of -$23M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.07x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of -64.14%. Ascendis Pharma AS's return on equity of -880.05% beat Evaxion Biotech AS's return on equity of --.

Ascendis Pharma AS has a consensus price target of $211.35, signalling upside risk potential of 48.14%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 777.48%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.540, which suggesting that the stock is 45.961% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Ascendis Pharma AS's net income of -$41M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.07x versus 0.42x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -880.05% beat NuCana PLC's return on equity of --.

Ascendis Pharma AS has a consensus price target of $211.35, signalling upside risk potential of 48.14%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 13047.91%. Given that NuCana PLC has higher upside potential than Ascendis Pharma AS, analysts believe NuCana PLC is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.540, which suggesting that the stock is 45.961% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $185.4M, which are larger than NuCana PLC quarterly revenues of --. Ascendis Pharma AS's net income of -$41M is lower than NuCana PLC's net income of -$836.1K. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.07x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -22.12% compared to Ascendis Pharma AS's net margin of 32.95%. Ascendis Pharma AS's return on equity of -880.05% beat Novo Nordisk AS's return on equity of 86.85%.

Ascendis Pharma AS has a consensus price target of $211.35, signalling upside risk potential of 48.14%. On the other hand Novo Nordisk AS has an analysts' consensus of $106.03 which suggests that it could grow by 69.52%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.540, which suggesting that the stock is 45.961% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.645%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.58% to investors and pays a quarterly dividend of $1.10 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ascendis Pharma AS quarterly revenues are $185.4M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Ascendis Pharma AS's net income of -$41M is lower than Novo Nordisk AS's net income of $4B. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 19.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.07x versus 6.63x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.